Net Pals Net Pals
Résultats de Recherche
Voir tous les résulats
  • Nous rejoindre
    Se connecter
    S’enregistrer
    Rechercher
    Mode nuit

Rechercher

Découvrez de nouvelles personnes, créer de nouvelles connexions et faire de nouveaux amis

  • Fil d’actualités
  • EXPLORER
  • Pages
  • Groupes
  • Evènements
  • Reels
  • Blogs
  • Marketplace
  • Offres
  • Emplois
  • Articles
  • Blogs
  • Utilisateurs
  • Pages
  • Groupes
  • Evènements
  • anjushinde13 Ajouter une nouvelle offre d'emploi Health
    2026-07-22 10:16:31 - Traduire -
    Common Drugs Use In Ophthalmology Market Competitive Landscape Overview
    The Common Drugs Use In Ophthalmology Market continues to expand as ophthalmologists, optometrists, and eye care specialists increasingly rely on established pharmacological agents to manage the growing spectrum of ocular diseases affecting vision and quality of life. With common ophthalmic drugs including anti-VEGF agents, prostaglandin analogs, corticosteroids, antibiotics, anti-allergy...
    0 Commentaires 0 Parts 371 Vue 0 Aperçu
    Connectez-vous pour aimer, partager et commenter!
  • mahir007 Ajouter une nouvelle offre d'emploi Autre
    2026-11-18 10:01:12 - Traduire -
    Aflibercept Market Size, Share, Trends & Forecast 2033
    Executive Summary Aflibercept Market Size and Share Analysis ReportCAGR ValueData Bridge Market Research analyses that the aflibercept market which was USD 8,343.15 million in 2022, and would rocket up to USD 13,911.94 million by 2030, and is expected to undergo a CAGR of 5.40% during the forecast period. This indicates that the market value. “Hospitals” dominates the end user...
    0 Commentaires 0 Parts 5 Vue 0 Aperçu
    Connectez-vous pour aimer, partager et commenter!
  • EthanWalker Ajouter une nouvelle offre d'emploi Autre
    2026-10-23 22:16:07 - Traduire -
    Alvotech (ALVO) files first known Eylea 8 mg biosimilar application in Europe
    Alvotech and Advanz Pharma sent AVT29 to the European Medicines Agency on 14 October 2026 as a line extension to Mynzepli, the Eylea 2 mg biosimilar. Alvotech (ALVO) and its partner Advanz Pharma submitted AVT29 to the European Medicines Agency on 14 October 2026, according to a company release issued the same day. AVT29 is a proposed biosimilar to Eylea 8 mg, the higher-dose form of...
    0 Commentaires 0 Parts 2KB Vue 0 Aperçu
    Connectez-vous pour aimer, partager et commenter!
© 2026 Net Pals French
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
Environ Conditions générale de vente Confidentialité Cookies Acceptable Use Contactez nous Annuaire